Welcome to CHARTER

Welcome to CHARTER as a Resource

The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study was first funded in September 2002 in response to NIMH RFA 00-AI-0005 to explore the changing presentation of HIV neurological complications in the context of emerging antiviral treatments such as highly active antiretroviral therapy (HAART). Current public funding includes grants from the National Institute of Health (NIH), the National Institute of Mental Health (NIMH) and the National Institute of Neurological Disorders and Stroke (NINDS) via the CHARTER Extension (NIMH/NINDS Award Number HHS-N-271-2010-00036C) and CHARTER As A Resource (NIH/NIMH/NINDS Award Number HHSN271201000030C).

CHARTER’s study aims are to determine how central and peripheral nervous system complications of HIV are affected by different histories and regimens of antiretroviral therapy (ART). Participants receive comprehensive neuromedical, neurocognitive, and laboratory examinations, with a subset undergoing host/viral genetic characterization and neuroimaging. In order to have a broad representation of participant characteristics, CHARTER is conducted at six performance sites nationally whose activities are coordinated by UCSD, the principal grantee institution, which includes several technical, scientific, and administrative cores to guide the work.




CHARTER Investigators Present at CROI 2015

The 22nd Annual Conference on Retroviruses and Opportunistic Infections (CROI) occurs from February 23 - 26 in Seattle, Washington.

CROI brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases.


CHARTER Manuscript Highlighted in Neurology

Dr. Igor Grant and the CHARTER Group have a featured article in the June 2014 issue of Neurology,  “Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline”.  Their study presents further evidence that HIV-associated neurocognitive disorders remain prevalent despite combination antiretroviral therapy.  The study demonstrates that early asymptomatic neurocognitive impairment (ANI) confers an increased risk and faster development of functional/symptomatic decline in individuals with HIV disease progression.  These findings highlight the importance of identifying those with ANI in the clinic early on to offer an opportunity to modify treatment to delay progression to symptomatic/functional decline.

Click Here for link to Pubmed - and full article when available in Pubmed Central.

To Cite:

Grant I, Franklin DR, Deutsch R, Woods SP, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Collier AC, Marra CM, Clifford DB, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Heaton RK, for the CHARTER Group.  (2014). Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology, 82(23), 2055-2062. PMID: 24814848


Abdominal Obesity Contributes to Cognitive Impairment in HIV

CHARTER investigators have published evidence that neurocognitive (NC) function in HIV-infected individuals was significantly linked to abdominal obesity, systemic inflammation, and immune activation.  Abdominal obesity and an increased risk of NC decline have previously been reported for non HIV-infected populations.  These findings may be especially relevant for HIV-infected individuals already having an increased risk of NC impairment from HIV infection, as abdominal obesity and other metabolic risk factors may be mitigated by lifestyle changes and treatment.

Click Here to read in Pubmed.

To Cite:

Sattler F, He J, Letendre S, Wilson C, Sanders C, Heaton R, Ellis R, Franklin D, Aldrovandi G, Marra CM, Clifford D, Morgello S, Grant I, Mccutchan JA, for the CHARTER Group.  (2014). Abdominal obesity contributes to neurocognitive impairment in HIV infected patients with increased inflammation and immune activation. Journal of Acquired Immune Deficiency Syndromes (1999), Epub. Dec. 2. PMID: 25469522


CHARTER Longitudinal Neurocognitive Data Unveiled at AIDS 2014

Dr. Robert Heaton presents the longitudinal data from the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study at the 20th International AIDS Conference (AIDS 2014) being held from 20-25 July 2014 at the Melbourne Convention and Exhibition Centre, in Melbourne, Australia.

Key points of the presentation include that neurocognitive change (NC) change is common in HIV infection, there are clinical and biological predictors of NC change, that the increased comorbidity burden and factors associated with Hispanic ethnicity deserve more attention in clinical care of HIV+ individuals, and that consistent use of ART to maintain virologic control may protect the central nervous system and improve NC outcomes.

To Cite:

Heaton RK, Franklin DR, Deutsch R, Letendre SL, Ellis RJ, Blackstone K, Marquine MJ, Woods SP, Vaida F, Atkinson JH, Marcotte TD, McCutchan JA, Collier AC, Marra CM, Clifford DB, Gelmen BB, McArthur JC, Morgello S, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Grant I, for the CHARTER Group.  (IP). Neurocognitive change in the era of HIV combination antiretroviral therapy: A longitudinal CHARTER Study. 20th International AIDS Conference.



  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  Next 
  •  End 
  • »

Page 1 of 3

Sponsored by NIH/NIMH/NINDS HHSN271201000036C & HHSN271201000030C

Copyright ©2010 CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH | University of California, San Diego | HNRP | For questions regarding this site, please contact the webmaster